3737 Market Street
About Spark Therapeutics
Spark Therapeutics is developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials with the potential to be the first approved gene therapy in the United States, and the first approved treatment to address the significant unmet needs of patients living with blindness due to inherited retinal dystrophies.
Additionally, the company has clinical and preclinical programs in other inherited retinal dystrophies and hematological disorders, and a proprietary manufacturing platform that has successfully supported human gene therapy trials across diverse therapeutic areas and routes of administration. Spark’s founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines.
Spark is based in Philadelphia, PA and was spun out of The Children's Hospital of Philadelphia in October 2013. In May 2014, Spark announced the completion of a $72.8 million Series B financing led by Sofinnova Ventures, bringing the company's total funding raised to $82.8 million to-date. To learn more about Spark visit www.sparktx.com.
Founders: Jeffrey Marrazzo, J. Fraser Wright and Katherine High
CEO: Jeffrey Marrazzo
CTO: J. Fraser Wright
CSO (Scientific): Katherine High
Please click here for Spark Therapeutics job opportunities.
Please click here for clinical trial information.
FOLLOW SPARKS THERAPEUTICS:
Tweets by Sparks Therapeutics
120 articles with Spark Therapeutics
Roche and Spark initially agreed to the acquisition in February of this year. The deal has had mutiple delays due to regulatory scrutiny.
As fireworks illuminate the night skies across the United States this weekend in celebration of Independence Day, BioSpace takes a look at some of the highlights of the pharma industry from the first half of 2019 and earlier that provides millions of patients with the independence of health.
6/27/2019According to the poll results, 78% of respondents agree that the high costs of a gene therapy treatment are worth it, due to the fact that these options are seen as potential cures for disease.
Invitae Announces ID YOUR IRD Program to Expand Access to Genetic Testing for Inherited Retinal Disorders
Genetic testing can identify causes of rare, progressive eye disorders
Government agencies in the United States and U.K. are scrutinizing Roche's planned acquisition of the gene therapy company.
The companies said they planned to give the government additional time to review the deal. This is the third delay.
4/26/2019This is the second extension that has been filed, this time delaying it until June 3. The companies indicate it is because U.S. authorities are taking longer than expected to review the deal.
Spark Therapeutics Announces Sponsorship of Believe Limited’s First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation’s Bleeding Disorders Conference
The Science Fair™ aims to engage and educate patients, families and caregivers affected by bleeding
April 17, 2019 is the 29th World Hemophilia Day, a designated day to create awareness of the disease. Hemophilia is one of a number of bleeding disorders. The blood of people with hemophilia does not clot normally as the result of insufficient clotting factor. As a result, they can bleed for a lo...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Spark Therapeutics, Inc. - ONCE
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Spark Therapeutics, Inc. relating to the sale of the Company to Roche Holdings, Inc.
Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics, said his company is the only biotech company that has successfully commercialized a gene therapy for a genetic disease in the United States.
Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium™
Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today the presentation of preclinical data for SPK-3006 for Pompe disease and SPK-1001 for CLN2 disease, a form of Batten disease, on Wednesday, Feb. 6, 2019, at the 15th Annual WORLDSymposium™ in Orlando, FL.
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 30 Life Science Startups to Watch in the U.S. from 2015.
Synthego Snags $110 Million in Series C to Advance Vision of Making CRISPR Technology More Available
10/23/2018Genome engineering company Synthego received an infusion of $110 million from a Series C financing round led by Peter Thiel’s Founders Fund. The funds will be used to accelerate the company’s vision to make CRISPR technology more accessible to researchers.
10/22/2018The U.S. Bureau of Labor Statistics predicts a 7 percent increase in jobs for biomedical engineers and a 13 percent increase in medical scientists.
Researchers at Johns Hopkins, the University of California, San Diego, and the National Institute of Mental Health grew retinas in petri dishes, and discovered fundamental factors involved in the development of vision and color vision.
Virion Therapeutics, LLC Announces its Inaugural Board of Directors and Scientific Advisory Board Members
Virion Therapeutics, LLC today announced the appointment of its inaugural Board of Directors and Scientific Advisory Board.
Recently, BioSpace posted a question on its website, under the heading, “We Want to Hear from You! Top Life Sciences Trends.” Let’s take a look at the five trends survey participants mentioned.
8/16/2018As gene therapies have become reality, the U.S. government is removing some special regulations that had been set up long ago over concerns of exotic safety risks.
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.